ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006

Int J Clin Pharmacol Ther. 2002 Dec;40(12):567-8. doi: 10.5414/cpp40567.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Aged
  • Benzenesulfonates / administration & dosage
  • Benzenesulfonates / pharmacology*
  • Biomarkers
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Middle Aged
  • Mitogen-Activated Protein Kinase 1 / metabolism*
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases / metabolism*
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Phosphorylation
  • Proto-Oncogene Proteins c-raf / antagonists & inhibitors*
  • Pyridines / administration & dosage
  • Pyridines / pharmacology*
  • Sorafenib

Substances

  • Benzenesulfonates
  • Biomarkers
  • Enzyme Inhibitors
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Sorafenib
  • Proto-Oncogene Proteins c-raf
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases